

Anesthesiology  
81:1235-1244, 1994  
© 1994 American Society of Anesthesiologists, Inc.  
J. B. Lippincott Company, Philadelphia

## Localization of Messenger RNA for Three Distinct $\alpha_2$ -Adrenergic Receptor Subtypes in Human Tissues

### Evidence for Species Heterogeneity and Implications for Human Pharmacology

Dan E. Berkowitz, M.D.,\* David T. Price, M.D.,† Elizabeth A. Bello, M.D.,‡ Stella O. Page,\*  
Debra A. Schwinn, M.D.§

**Background:**  $\alpha_2$ -Adrenergic receptor ( $\alpha_2$ AR) agonists have become important adjuncts as anesthetic agents. They act by binding to  $\alpha_2$ ARs on the surface of cell membranes and cause centrally mediated sedation and analgesia.  $\alpha_2$ ARs also contribute to other aspects of physiologic regulation. Three subtypes of  $\alpha_2$ ARs ( $\alpha_{2-C2}$ ,  $\alpha_{2-C4}$ , and  $\alpha_{2-C10}$ ) have been described using molecular and pharmacologic techniques. We recently demonstrated species heterogeneity in the distribution of  $\alpha_1$ -adrenergic receptor subtypes, therefore making it imperative to analyze the distribution of  $\alpha_2$ AR subtypes in human tissues. This information may have importance in the understanding of potential side effects of administration of  $\alpha_2$ AR subtype-selective agonists for anesthesia in humans.

**Methods:** RNA extracted from human tissues was analyzed by using quantitative ribonuclease protection assays to determine  $\alpha_2$ AR subtype messenger RNA (mRNA) expression in cardiovascular, central nervous system, and peripheral tissues.

**Results:**  $\alpha_2$ AR mRNA is present in greatest concentrations in human kidney, followed by aorta > spleen > heart = lung.  $\alpha_{2-C4}$  mRNA predominates in heart, lung, aorta, cerebral cortex, cerebellum, spleen, kidney, and adrenal gland;  $\alpha_{2-C2}$  mRNA in liver; and  $\alpha_{2-C10}$  mRNA in pancreas and small intestine. Hence  $\alpha_2$ AR subtype mRNA distribution is tissue-selective and differs from that reported for rat.

**Conclusions:** (1) On comparison with previous research we find possible species heterogeneity in  $\alpha_2$ AR subtype mRNA distribution (rat vs. human) for all three  $\alpha_2$ AR subtypes. (2) We demonstrate the presence and subtype heterogeneity of  $\alpha_2$ AR subtype mRNA in both brain and peripheral tissues. (3) Significant concentrations of  $\alpha_2$ AR mRNA are present in adult human heart. These findings have important implications for our understanding of human adrenergic physiology, provide a possible explanation for the existence of pharmacologically similar yet distinct  $\alpha_2$ AR subtypes, and may be important for the rational development of  $\alpha_2$ AR subtype-selective anesthetics and other therapeutic agents for use in treating human diseases. (Key words: Cardiovascular system: blood vessels. Heart: myocardium. Receptors: adrenergic;  $\alpha$ -adrenergic. RNA: antisense; probes.)

CATECHOLAMINES such as epinephrine and norepinephrine mediate their effects by binding to three different major families of adrenergic receptor (AR) subtypes.<sup>1,2</sup> ARs are encoded by different genes and are members of the larger family of guanine nucleotide-binding protein-coupled receptors.<sup>3,4</sup>  $\alpha_2$ -Adrenergic receptor ( $\alpha_2$ AR) activation leads to inhibition of adenylyl cyclase activity, downregulation of  $Ca^{2+}$  channels, and activation of  $K^+$  channels, leading to hyperpolarization of the cell.<sup>5</sup> These effects have important consequences in cardiovascular physiology, smooth muscle contraction, neurotransmitter release, and modulation of sympathetic outflow from the central nervous system.<sup>6</sup> Whereas both  $\beta$ AR and  $\alpha_1$ -adrenergic receptor ( $\alpha_1$ AR) subtypes have been implicated in myocardial inotropy,  $\alpha_2$ ARs appear to have a limited role in the heart, being generally localized to coronary arteries and prejunctional cardiac nerves but not postjunctional myocardium.<sup>7,8</sup>  $\alpha_2$ ARs are also known to have important roles in peripheral tissues such as the liver (glycogenolysis and gluconeogenesis), pancreas (decreased secretion of insulin from islet  $\beta$ -cells), spleen (contraction of capsule), and kidney (yet undeter-

\* Department of Anesthesiology.

† Department of Surgery.

‡ Department of Anesthesiology and Department of Pediatrics (Critical Care Division).

§ Department of Anesthesiology, Department of Surgery, and Department of Pharmacology.

Received from the Duke University Medical Center, Durham, North Carolina. Accepted for publication June 27, 1994. Supported in part by the Foundation for Anesthesia Education and Research—Schering-Plough Research Fellowship (D.E.B.) and by National Institutes of Health grants HL07063 (to E.A.B.) and HL02490 and HL49103 (to D.A.S.). Received second-place award in the Resident's Essay Competition of the ASA, 1993 (D.E.B.)

Address reprint requests to Dr. Schwinn: Department of Anesthesiology, Box 3094, Duke University Medical Center, Durham, North Carolina 27710.

mined role in water reabsorption in both proximal and distal tubules).<sup>9</sup> Finally,  $\alpha_2$ ARs mediate potent sedative and hypnotic effects and modulate pain pathways at the level of the spinal cord.<sup>10</sup> Because of these effects,  $\alpha_2$ AR agonists have become important adjuncts in the armamentarium of drugs used by the anesthesiologist. They are also increasingly becoming targets for intervention and therapy in various human diseases.

Three  $\alpha_2$ AR subtypes have been described using molecular and pharmacologic techniques. Cloned  $\alpha_2$ AR subtypes have been designated  $\alpha_{2-C10}$ ,  $\alpha_{2-C4}$ , and  $\alpha_{2-C2}$ , according to the human chromosomal localization of the gene.<sup>11-15</sup> Cross-referencing these cloned  $\alpha_2$ ARs with pharmacologic subtypes previously described by Bylund and colleagues<sup>16-18</sup> demonstrates that the  $\alpha_{2-C10}$ AR corresponds to the pharmacologic  $\alpha_{2A}$  subtype (and represents the platelet  $\alpha_2$ AR), the  $\alpha_{2-C4}$ AR corresponds to the pharmacologic  $\alpha_{2C}$  subtype, and the  $\alpha_{2-C2}$ AR corresponds to the pharmacologically derived  $\alpha_{2B}$  subtype. ||

The physiologic relevance of three distinct  $\alpha_2$ AR subtypes is not yet known. Recently we have found species heterogeneity in the distribution of  $\alpha_1$ AR subtypes,<sup>19</sup> making it imperative to analyze the localization of  $\alpha_2$ AR subtypes in human tissues, in order to help answer questions about the physiologic function of receptor subtypes and their perturbations in human pathophysiologic states. Such information has important implications for understanding potential side-effects of administration of  $\alpha_2$ AR subtype selective agonists for anesthesia in humans. In this report we describe the expression of  $\alpha_2$ AR subtypes messenger RNA (mRNA) in human tissue using the ribonuclease (RNase) protection assay, a technique that is sensitive for quantitating specific mRNA species. Our results indicate that distribution of  $\alpha_2$ AR subtype mRNA is somewhat tissue selective and species specific. Furthermore we demonstrate the presence of  $\alpha_2$ AR mRNA in adult human heart. These findings have potentially important implications for expanding our understanding of human adrenergic physiology and may be important for the rational development of  $\alpha_2$ AR subtype selective anes-

thetics and other therapeutic agents for use in various human diseases.

## Materials and Methods

### Cell Culture

Chinese hamster ovary cells stably expressing individual human  $\alpha_2$ ARs ( $\alpha_{2-C10}$ ,  $\alpha_{2-C2}$ ,  $\alpha_{2-C4}$ ,  $\sim 1$  pmol receptor/mg total protein)<sup>9,10,13</sup> used to test sensitivity and specificity of human  $\alpha_2$ AR subtype mRNA probes, were generously provided by Robert Lefkowitz, of Duke University. These cells were grown as monolayers in Dulbecco's modified Eagle's medium (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100  $\mu$ g/ml) in 5% CO<sub>2</sub> at 37°C. Selection was maintained by adding the antibiotic G418 (0.8 mg/ml) to the media.

### Human Tissue Preparation and Messenger RNA Isolation

Normal adult human tissues were obtained either from rapid autopsy (within 1–3 h of death), from organ donor patients (within 30 min of death), or as discarded tissues during surgery (within 5 min of dissection) with appropriate institutional approval. Tissues were snap-frozen in liquid nitrogen and stored at  $-70^\circ\text{C}$ . Total RNA was extracted from tissue samples by the guanidinium isothiocyanate–cesium chloride gradient method.<sup>20</sup> RNA samples were then quantitated using a spectrophotometer at 260 and 280 nm, aliquoted into 30- $\mu$ g samples, and stored at  $-70^\circ\text{C}$  as ethanol precipitates.

### Human Complementary DNA Constructs and RNA Probes

The complementary (cDNA)  $\alpha_{2-C10}$ AR plasmid construct consists of a 0.324-kb *Bgl*III/*Acc*I (restriction endonucleases used to “cut” and allow “pasting” of DNA at unique sites) fragment in pSP72 (a transcription vector used to generate cRNA probe) (Promega, Madison, WI) (nucleotide 318–642), encoding the third through fifth transmembrane domains.<sup>11</sup> The  $\alpha_{2-C4}$ AR cDNA construct consists of a 0.348-kb *Sac*I/*Acc*I fragment in pGEM-3Z (Promega) (nucleotide 377–725), encoding the third transmembrane domain through the initial third intracellular loop.<sup>12</sup> The  $\alpha_{2-C2}$ AR cDNA construct consists of a 0.333-kb *Pst*I/*Bam*HI fragment in pGEM-3Z (Promega) (nucleotide 1395–1728),

|| When referring to the human cloned receptor subtypes, we will use the human chromosomal location classification ( $\alpha_{2-C2}$ ,  $\alpha_{2-C4}$ , and  $\alpha_{2-C10}$ ). When referring to the rat and other species homolog subtypes, as well as human protein binding data, we will use the pharmacologic classification ( $\alpha_2A$ ,  $\alpha_2B$ , and  $\alpha_2C$ ). This is done to be strictly scientifically correct.  $\alpha_{2-C2} = \alpha_2B$ ;  $\alpha_{2-C4} = \alpha_2C$ , and  $\alpha_{2-C10} = \alpha_2A$ .

corresponding to the initial 3' untranslated region of the receptor gene.<sup>15</sup> To compare concentrations of  $\alpha_2$ AR mRNA with  $\alpha_{1C}$ AR mRNA in human heart, a human  $\alpha_{1C}$ AR probe was constructed from human cDNA using a 0.322-kb *PvuII/HindIII* fragment inserted into pGEM-4Z (Promega) corresponding to the third extracellular loop through the initial carboxyl terminus of the human  $\alpha_{1C}$ AR cDNA.<sup>21</sup> Control  $\beta$ -actin probe was received as a gift from Joanne M. Pyper, Johns Hopkins University School of Medicine (Baltimore, MD). This probe consists of a 104-bp fragment of the human  $\beta$ -actin gene cloned into the *AccI/HindII* sites of the vector pGEM-4Z (Promega). Linearized cDNA constructs were used to make both single stranded sense (nonradiolabeled control) and antisense (radiolabeled) RNA probes using either T7 or SP6 RNA polymerase as previously described.<sup>22</sup> Probes were radiolabeled with <sup>32</sup>P- $\alpha$ -CTP (New England Nuclear-DuPont). Due to varying lengths of polylinker sequence between RNA polymerase initiation sites and the constructs described above, predicted antisense (specific) probe lengths are as follows:  $\alpha_{2-C10}$  = 362 nucleotides,  $\alpha_{2-C4}$  = 368 nucleotides,  $\alpha_{2-C2}$  = 364 nucleotides. Control sense/antisense RNA hybrids are slightly larger due to varying amounts of polylinker transcribed with sense strand RNA.

#### Ribonuclease Protection Assay

RNase protection assays were conducted as previously described by Zinn *et al.*<sup>23</sup> with the following modifications. In brief, 30  $\mu$ g of dried total RNA (from ethanol precipitates) was dissolved in 30  $\mu$ l of hybridization buffer (80% formamide, 40 mM piperazinediethanesulfonic acid, pH 6.4, 400 mM NaCl, 1 mM ethylenediaminetetraacetic acid) containing  $\sim 5 \times 10^5$  cpm of the cRNA probe. The solution was then heated for 5 min. at 85°C, followed by an overnight incubation at 55°C ( $\alpha_{1C}$  and  $\beta$ -actin) or 60°C (all three  $\alpha_2$  probes). RNase digestion was accomplished using 300  $\mu$ l of RNase solution (RNase A [40  $\mu$ g/ml, Sigma, St. Louis, MO] and RNase T1 [800 U/ml, Gibco/BRL] in 300 mM Na acetate and 5 mM ethylenediamine tetraacetic acid) at 30°C for 60 min and was terminated by addition of 10  $\mu$ l 20% sodium dodecyl sulfate and 2.5  $\mu$ l proteinase K (15 mg/ml) for 30 min at 37°C. After phenol-chloroform extraction, RNA was precipitated with 20  $\mu$ g transfer RNA as a carrier. After resuspension in 4  $\mu$ l loading buffer (80% formamide, 1 mM pH 8.0, 0.1% bromophenol blue, 0.1% xylene cyanol), the samples were separated by electrophoresis on a denaturing 8 M

urea/6% acrylamide gel, followed by drying and exposure to XAR-5 (Kodak) film for 12–48 h at  $-70^\circ\text{C}$ .

#### Quantitation

The quantitation of mRNA protected by the radiolabeled antisense probe was performed by a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). This technique converts <sup>32</sup>P-emitted radiation into phosphorescence. This technique is far more sensitive and linear over a longer range than autoradiography. Each gel was exposed for 24 h to PhosphorImager screens and volume integration of bands resulting from hybridization products was performed using gel image analysis computer software (Imagequant, Molecular Dynamics). Tenfold dilutions of single-strand sense RNA (100 ng to 1 pg) were included with each hybridization assay as controls. A standard curve was fit using saturation binding isotherms (InPlot; GraphPad, San Diego, CA), enabling interpolation of concentration of message in human tissue from protected hybridization bands.


## Results

#### Specificity of $\alpha_2$ -Adrenergic Receptor RNA Probes

To ensure specificity of the synthesized radiolabeled antisense human  $\alpha_2$ AR subtype selective probes, RNase protection assays were performed on total RNA extracted from Chinese hamster ovary cells stably expressing each cloned  $\alpha_2$ AR subtype. As shown in figure 1, all three  $\alpha_2$ AR subtype-specific probes protect a single predominant fragment without cross-hybridization.

#### RNA Isolation from Tissues

Total RNA was isolated from various human tissues including representative cardiovascular (heart, lung, and aorta), brain (cerebral cortex and cerebellum), and several clinically important peripheral tissues (liver, pancreas, spleen, kidney, and adrenal gland). To ascertain uniformity of RNA isolation procedures for each human tissue, RNase protection assays with  $\beta$ -actin probes were also performed in a representative number of samples;  $\beta$ -actin experiments demonstrated equivalent concentrations of  $\beta$ -actin mRNA in each tissue. In certain samples of pancreatic tissue the  $\beta$ -actin signal was decreased. This is not surprising because pancreas is known to contain large concentrations degrading enzymes.



**Fig. 1.** Ribonuclease protection assays were performed with radiolabeled antisense  $\alpha_2$ -adrenergic receptor ( $\alpha_2$ AR) subtype-selective RNA probes on total RNA extracted from Chinese hamster ovary (CHO) cells stably expressing each cloned  $\alpha_2$ AR subtype. All three  $\alpha_2$ AR subtype probes protected a single predominant fragment without cross-hybridization.


#### Quantitation of $\alpha_2$ -Adrenergic Receptor Subtype Messenger RNA in Human Tissues

As seen in figure 2, the  $\alpha_{2-C4}$ AR probe protects a 348-bp fragment, the  $\alpha_{2-C2}$  probe a 333-bp fragment, and the  $\alpha_{2-C10}$  probe a 324-bp fragment in a variety of human tissues. It is important to note that radiolabeled antisense RNA probes are slightly larger than final protected fragments due to varying amounts of polylinker RNA present in the probe and not in the mRNA product. In order to quantitate expression of each  $\alpha_2$ AR subtype in human tissues, known concentrations of unlabeled single-strand sense RNA (100 ng to 1 pg) were included as standards with each hybridization assay. A standard curve fit to protected sense strand RNA was used to interpolate the concentration of message in human tis-

ues from protected fragments. RNA standards saturate at approximately 10 ng (range 1–10 ng) sense RNA. The lower limits of resolution of this assay are 0.5–1 pg  $\alpha_2$ AR mRNA/30  $\mu$ g total RNA.  $\alpha_2$ AR mRNA ranged from 0–50 pg/30  $\mu$ g total RNA for all human tissues studied.

#### Expression of $\alpha_2$ -Adrenergic Receptor Subtype Messenger RNA in Human Tissues

Table 1 shows the quantitative distribution of  $\alpha_2$ AR subtype mRNA in human tissues. Note that RNA encoding all three  $\alpha_2$ AR subtypes is present in both human brain and peripheral tissues. Total  $\alpha_2$ AR mRNA levels are highest in human kidney, aorta, spleen, and heart (table 1). With the exception of liver, small intestine, and pancreas, the  $\alpha_{2-C4}$  subtype represents the majority of  $\alpha_2$ AR mRNA present in all human tissues studied (table 1). In particular,  $\alpha_{2-C4}$ AR mRNA predominates in human cardiovascular tissues (heart and aorta). Cardiovascular tissues express  $\alpha_{2-C2}$  subtype mRNA in lower concentrations whereas  $\alpha_{2-C10}$  mRNA is virtually absent in human myocardium but does represent some of  $\alpha_2$ AR mRNA in human aorta and lung, respectively.



**Fig. 2.** Representative autoradiograms from ribonuclease protection assays performed with a radiolabeled  $\alpha_{2-C4}$  ( $\alpha_{2C}$ ),  $\alpha_{2-C10}$  ( $\alpha_{2A}$ ), and  $\alpha_{2-C2}$  ( $\alpha_{2B}$ ) (adrenergic receptor antisense probes) in a variety of human tissues. Exposure times depicted are 24 ( $\alpha_{2-C4}$ ), 36 ( $\alpha_{2-C10}$ ), and 12 ( $\alpha_{2-C2}$ ) h. Autoradiograms were used only for screening because quantitation was performed using 24-h exposure to PhosphorImager screens, a process more sensitive than autoradiography for quantitation (see table 1 for semiquantitative results). Transfer RNA was the negative control.


$\alpha_2$ -ADRENERGIC RECEPTOR SUBTYPE mRNA IN HUMAN TISSUES**Table 1. Distribution of  $\alpha_2$ -Adrenergic Receptor Subtype mRNA in Human Tissues**

	$\alpha_{2-C2}$ ( $\alpha_{2B}$ )	$\alpha_{2-C4}$ ( $\alpha_{2C}$ )	$\alpha_{2-C10}$ ( $\alpha_{2A}$ )	n
<b>Cardiovascular</b>				
Heart (ventricle)	++	+++	-	2-3
Lung	+	+	++	2
Aorta	++	++++	++	3-4
<b>Brain</b>				
Cerebral cortex	±	++	+	2
Cerebellum	±	+	+	3
<b>Other peripheral tissues</b>				
Spleen	++	+++	++	3
Pancreas	±	+	++	4
Liver	++	+	-	3
Kidney	+	+++++	+	4
Adrenal	+	+	±	2
Small intestine	+	+	++	2

Semiquantitative analysis of the distribution of  $\alpha_2$ -AR subtypes in human tissues in pg/30  $\mu$ g of total RNA. The following represents the scale used: <1 pg, ±; 1-4 pg, +; 5-9 pg, ++; 10-19 pg, +++; 20-40 pg, ++++; >40 pg, +++++.

Although  $\alpha_1$ ARs have been documented to have positive inotropic effects in human and other mammalian ventricular tissue,  $\alpha_2$ ARs are not well described in adult human myocardium. Therefore, the presence of two  $\alpha_2$ AR subtype mRNA subtypes ( $\alpha_{2-C4}$  >  $\alpha_{2-C2}$ ) in relatively high concentrations in human left ventricular myocardium is surprising and novel. In order to investigate the relative abundance of  $\alpha_2$ AR compared to  $\alpha_1$ AR mRNA in human left ventricle, the highest expressing myocardial  $\alpha_2$ AR subtype ( $\alpha_{2-C4}$ ) was compared with the previously described highest expressing myocardial  $\alpha_1$ AR subtype ( $\alpha_{1C}$ ).<sup>24</sup> Figure 3 and table 2 demonstrates that  $\alpha_{2-C4}$  mRNA concentrations (15-19pg/30  $\mu$ g total RNA, n = 3) are approximately 30-fold lower than  $\alpha_{1C}$  mRNA (461-607 pg/30  $\mu$ g total RNA, n = 3) in human myocardial (left ventricular) tissue. Myocardial mRNA expression levels are remarkably consistent between patients for both  $\alpha_2$  and  $\alpha_1$ AR mRNA (table 1).

In addition to cardiovascular tissues,  $\alpha_2$ ARs are known to be present and have important physiologic roles in brain and peripheral tissues. Two human brain regions were examined in this study—cerebral cortex and cerebellum (table 1). Although present in fairly low concentrations overall, all three  $\alpha_2$ AR subtype mRNAs are present in each tissue. In these human brain regions,  $\alpha_{2-C4}$ AR mRNA represents the majority of  $\alpha_2$ AR mRNA, followed by  $\alpha_{2-C10}$ AR mRNA, and only a small percentage of  $\alpha_{2-C2}$ AR mRNA.



**Fig. 3.** To compare the quantities of  $\alpha$ -adrenergic receptor ( $\alpha$ AR) messenger RNA (mRNA) in human myocardium, ribonuclease protection assays were performed with probes recognizing mRNA for the most abundant myocardial  $\alpha_2$ AR ( $\alpha_{2-C4}$ ) and  $\alpha_1$ AR ( $\alpha_{1C}$ ). A single predominant protected fragment was seen for each AR (348-bp  $\alpha_{2-C4}$  and 322-bp  $\alpha_{1C}$ ); the lighter band above each protected fragment represents excess undigested probe. Quantitation of these radiolabeled protected fragments is reported in table 2.

In peripheral tissues, kidney and spleen have the highest levels of  $\alpha_2$ AR mRNA. Although possibly underestimated according to  $\beta$ -actin controls, pancreas and liver contain far less  $\alpha_2$ AR mRNA overall than spleen or kidney, as do small intestine, adrenal, and retina. In peripheral tissues the pattern of  $\alpha_2$ AR subtype mRNA distribution differs from brain or cardiovascular tissues. For example the vast majority of  $\alpha_2$ AR mRNA in human liver is of the  $\alpha_{2-C2}$  subtype. In pancreas and small intestine, where  $\alpha_2$ ARs are known to have important physiologic functions, the  $\alpha_{2-C10}$  subtype predominates. However, in human kidney, spleen and adrenal, the

**Table 2. Human Myocardial  $\alpha$ -Adrenergic Receptor Subtype mRNA Expression: Comparison of the Predominant  $\alpha_1$ -AR Subtype ( $\alpha_{1C}$ ) with the Predominant  $\alpha_2$ -AR Subtype ( $\alpha_{2-C4}$ ) in Ventricular Tissue**

	$\alpha_{2-C4}$ AR (pg/30 $\mu$ g total RNA)	$\alpha_{1C}$ AR (pg/30 $\mu$ g total RNA)	$\alpha_{1C}/\alpha_{2-C4}$ (ratio)
Heart 1	19	461	24
Heart 2	15	494	33
Heart 3	17	607	36
Mean $\pm$ SEM	17 $\pm$ 1	520 $\pm$ 24	

$\alpha_{2C4}$  subtype prevails, although other  $\alpha_2$ AR subtype mRNAs are present to varying degrees (table 1).

## Discussion

In this study,  $\alpha_2$ AR subtype selective mRNA distribution is examined in various human tissues. The physiologic significance of three distinct  $\alpha_2$ ARs is not yet known, but elucidating receptor subtype distribution may play an important role in ultimately understanding mechanisms of receptor function and their physiologic role in health and disease. It is important to note in interpreting the data, that mRNA levels do not necessarily reflect expressed, functional receptor protein. However, in general, the presence or absence of mRNA correlates with the presence or absence of receptor protein in a given tissue and hence may be important in conjunction with receptor protein studies in ultimately understanding the complexity of the AR system. It is also important to emphasize that although the RNase protection assay technique is extremely sensitive and can give you quantitative information about general receptor subtype mRNA in homogenized tissue, it gives no information about the cellular location of receptors within tissue, information that can only be gleaned from *in situ* hybridization. With this in mind, this study has three important findings: (1) species heterogeneity in  $\alpha_2$ AR subtype mRNA distribution; (2) relative organ selectivity in  $\alpha_2$ AR subtype mRNA distribution; and (3) the presence of relatively large concentrations of for  $\alpha_2$ AR in human heart.

Species heterogeneity of ARs is a complex issue. With regard to  $\alpha_2$ ARs, a number of studies have addressed the question of the distribution of  $\alpha_2$ AR subtype mRNA in rat tissues. The literature is, however, somewhat confusing and lacks consensus. Lorenz *et al.*,<sup>25</sup> using Northern analysis with human probes and rat tissues found  $\alpha_{2B}$  (also called  $\alpha_{2C2}$ ) mRNA expressed only in rat liver and kidney,  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) mRNA expressed only in the brain and not in peripheral tissues, and  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) mRNA expressed in both brain and peripheral tissues. Voigt *et al.*,<sup>26</sup> after the cloning of the rat homologue of the  $\alpha_{2C}$  (88% sequence homology with human  $\alpha_{2C4}$ AR), demonstrated its expression in high-stringency Northern blot analysis in rat brain, kidney, a small quantity in heart, and no expression in pancreas, liver, and lung. Lanier *et al.*<sup>27</sup> also isolated two  $\alpha_2$ AR rat clones, corresponding to the  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) and  $\alpha_{2A}$  ( $\alpha_{2C10}$ ), and demonstrated using Northern Blot analysis mRNA expression of  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) only in rat brain but

**Table 3. Summary of the Distribution of  $\alpha_2$ -AR Subtype mRNA in Rat Tissues**

	$\alpha_{2B}$ ( $\alpha_{2C2}$ )	$\alpha_{2C}$ ( $\alpha_{2C4}$ )	$\alpha_{2A}$ ( $\alpha_{2C10}$ )
Heart	+	—	—
Adult lung	++	—	+
Brain	+	+	+++
Liver	++	—	—
Kidney	+++++++	+	++
Spleen	—	—	+++++

Compiled from previously published data using RNase protection assay data.<sup>28</sup> Note that the range is an arbitrary scale from — to ++++++++ as presented by the original authors.

not in heart and kidney as Voigt *et al.*<sup>26</sup> had demonstrated. Differences between investigators in the localization of  $\alpha_2$ AR subtype mRNA in rat tissues may be accounted for by differences in Northern analysis methods including stringency of hybridization and possibly the use of human probes with rat tissues. Handy *et al.*<sup>28</sup> have recently investigated the distribution of rat  $\alpha_2$ AR subtypes expression using RNase protection assays. Their data is summarized in table 3 and shows expression of  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) mRNA in rat brain, kidney and spleen and a small amount in rat lung;  $\alpha_{2B}$  ( $\alpha_{2C2}$ ) mRNA expressed highly in rat kidney with weak hybridization in liver, adult and neonatal lung, and heart; and  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) mRNA expressed in rat brain with weak hybridization in rat kidney. Because RNase protection assay experiments are more sensitive and specific than Northern analysis, and correspond to our current methods, this data will be used in drawing conclusions on species heterogeneity. Differences in the distribution of  $\alpha_2$ AR subtype mRNA distribution between human and rat are immediately apparent (tables 1 and 3). In human cardiovascular tissues,  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) mRNA clearly predominates, whereas in rat  $\alpha_{2B}$  ( $\alpha_{2C2}$ ) mRNA predominates. However in brain tissues, rat and human have similar  $\alpha_2$ AR subtype mRNA distribution with  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) and  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) mRNA predominating. Human kidney contains almost exclusively  $\alpha_{2C}$  subtype mRNA, whereas rat kidney contains predominantly  $\alpha_{2B}$  mRNA. Liver, however, contains mostly  $\alpha_{2B}$  subtype mRNA in both human and rat. Species differences in the location of  $\alpha_2$ AR subtypes have potentially important consequences for human physiology; thus it is important to define  $\alpha_2$ AR subtype distribution in human tissues.

Three important categories of human tissues have been considered in this study—brain, cardiovascular

tissues, and non-cardiovascular peripheral organs; each of these will be discussed in order.  $\alpha_2$ ARs subserve a number of functions in the central nervous system important in integrating autonomic, visceromotor, and affective information.  $\alpha_2$ ARs are involved in central modulation of blood pressure, control of affect, sedation, nociception, and interact with opiate receptors to suppress opiate withdrawal. Perala *et al.*,<sup>29</sup> who investigated the distribution of the  $\alpha_{2C4}$  and  $\alpha_{2C10}$  in various human and fetal brain regions, found  $\alpha_{2C10}$  to be the predominant  $\alpha_2$ AR subtype mRNA in adult cerebral cortex and cerebellum. Ordway *et al.*,<sup>30</sup> using radioligand-binding studies, have demonstrated the  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) to predominate in most brain regions with the  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) being expressed in high concentrations in the caudate nucleus. Although we demonstrate the presence of  $\alpha_{2C10}$  in human cerebral cortex, we find greater expression of  $\alpha_{2C4}$  mRNA in both cerebral cortex and cerebellum in adult brain. Zeng *et al.*,<sup>14</sup> using Northern blot analysis in rat tissues, found the  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) subtype to be prominent in the midbrain and brainstem, with the cortex having roughly equal amounts of  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) and  $\alpha_{2C}$  ( $\alpha_{2C4}$ ). The  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) subtype predominated in the cerebellum. Rosin *et al.*,<sup>31</sup> using an antibody specific for the  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) AR subtype, demonstrated the presence of receptor protein in brainstem and spinal cord predominantly in areas involved in the control of autonomic function. In a comprehensive study of the localization of  $\alpha_2$ AR subtype mRNA in the rat brain using *in situ* hybridization, Nicholas *et al.*<sup>32</sup> demonstrated  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) mRNA in rat brain areas containing central nonadrenergic and adrenergic cell groups (locus ceruleus, reticular thalamic nucleus, as well as deep cerebellar nuclei),  $\alpha_{2C}$  ( $\alpha_{2C4}$ ) expressed in cerebral cortex, cerebellar cortex, and deep cerebellar nuclei, and  $\alpha_{2B}$  ( $\alpha_{2C2}$ ) only weakly labeling a small area of thalamus. Because deeper nuclei appear to contain distinct  $\alpha_2$ AR subtype mRNA compared with more superficial layer of cortex in rat,<sup>32</sup> the discrepancy in our data and that of Perala *et al.*<sup>29</sup> may possibly reflect the lack of deeper nuclei present in our cerebral cortical and cerebellar brain samples.

We clearly demonstrate the presence of  $\alpha_2$ AR mRNA in adult human left ventricular myocardium. Only  $\alpha_{2C4}$  (78%) and  $\alpha_{2C2}$  (22%) subtype mRNAs are present in human heart. When compared to the predominant  $\alpha_1$ AR subtype mRNA in human myocardium, the  $\alpha_{1C}$ AR,<sup>33</sup>  $\alpha_{2C4}$  mRNA is present in approximately 30-fold lower concentrations. However, overall  $\alpha_2$ AR mRNA concentrations in human myocardium are some

of the highest determined in this study, suggesting that these receptors may possibly be physiologically important. Whereas postsynaptic myocyte  $\beta$ ARs predominate in mediating inotropy and chronotropic responses, and  $\alpha_1$ ARs mediate inotropic and arrhythmogenic responses,<sup>34</sup> postsynaptic  $\alpha_2$ ARs have never been well described in human myocardium. In adult rat, low levels of  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) mRNA do appear to be present by Northern blot analysis.<sup>25</sup> Transient relatively high expression of  $\alpha_2$ ARs (up to 85 fmol/mg total protein) as assessed by ligand binding techniques,<sup>35</sup> occurs in fetal rat heart; however rat myocardial  $\alpha_2$ AR concentrations decrease dramatically by birth. In functional assays, Housmans *et al.*<sup>36</sup> found dexmedetomidine to have no inotropic actions in isolated ferret papillary muscle, and Flacke *et al.*<sup>37</sup> reported no direct effect of dexmedetomidine in isolated dog hearts. Because  $\alpha_2$ ARs have important presynaptic roles, speculation regarding a potential postsynaptic role for myocardial  $\alpha_2$ ARs must await further studies (*i.e.*, *in situ* hybridization to determine if the  $\alpha_2$ AR mRNA is localized in the myocardial cells themselves). Thus  $\alpha_2$ AR mRNA detected in the heart may represent coronary vascular  $\alpha_2$ AR, presynaptic  $\alpha_2$ AR regulating cardiac sympathetics, or postsynaptic  $\alpha_2$ ARs. In other cardiovascular tissues,  $\alpha_{2C4}$ AR mRNA predominates in human aorta. This is in striking contrast to rat aorta which expresses only  $\alpha_{2A}$  ( $\alpha_{2C10}$ ) AR mRNA.<sup>25,38,39</sup> In this regard, it will be important to ascertain whether other human vascular beds, particularly smaller resistance vessels, also contain predominantly the  $\alpha_{2C4}$ AR mRNA subtype. The last cardiovascular tissue we studied was the lung. Ligand binding and functional data demonstrate the presence of tracheobronchial  $\alpha_1$  and  $\alpha_2$ ARs which may modulate bronchoconstriction in many species.<sup>40</sup> In addition, neonatal rat lung is the prototypic tissue used in the definition of the  $\alpha_{2B}$  ( $\alpha_{2C2}$ ) AR subtype. Although we demonstrate some  $\alpha_{2C2}$  ( $\alpha_{2B}$ ) AR mRNA in the lung, the predominant subtypes are  $\alpha_{2C4}$  and  $\alpha_{2C10}$ .  $\alpha_2$ AR species differences in cardiovascular tissues may be important in the design of drugs for treatment of human cardiovascular diseases, as well as predicting side-effects of future  $\alpha_2$ AR subtype selective drugs for use in anesthesia and analgesia.

$\alpha_2$ ARs also have important roles in non-cardiovascular peripheral organs.  $\alpha_2$ ARs are clearly important in mediating gastrointestinal function such as endocrine function of the pancreas,<sup>34,41</sup> specifically, epinephrine inhibits the release of insulin stimulated by glucose via  $\alpha_2$ ARs. Phentolamine (a nonspecific  $\alpha$ AR antagonist)

and yohimbine (a specific  $\alpha_2$ AR antagonist) increase plasma insulin immunoreactivity in mice, whereas phenoxybenzamine and prazosin (specific  $\alpha_1$ AR antagonists) have no such effect;<sup>42</sup> radioligand binding assays confirm these results.<sup>43</sup> Our data demonstrate that the  $\alpha_{2-C10}$  subtype predominates in human pancreas, followed by  $\alpha_{2-C4}$ . *In situ* hybridization will be needed to ascertain which of these two  $\alpha_2$ AR subtype mRNAs is restricted to specific locations such as  $\beta$ -cells of pancreatic islets where insulin release occurs. In other gastrointestinal tissues such as the small intestine,  $\alpha_2$ ARs possess antisecretory properties, therefore  $\alpha_2$ AR agonists have recently been proposed to be a promising new class of antidiarrheal drugs in humans.<sup>44</sup> Our data from the small intestine of only one patient demonstrates that  $\alpha_{2-C10}$  mRNA predominates (although  $\alpha_{2-C4}$  subtype mRNA is also present) in this portion of the gastrointestinal tract in humans, and confirms the RNase protection assay receptor protein data of Valet *et al.*<sup>45</sup> In the kidney,  $\alpha_{2-C4}$  mRNA clearly predominates, being present in both the cortex and medulla (data not shown). Because  $\alpha_2$ ARs may be involved in either regulation of blood flow associated with renal arterioles or may play a role in the regulation of sodium and water homeostasis,  $\alpha_{2-C4}$ ARs may be involved in these functions. It is interesting that although the gene encoding the  $\alpha_{2-C4}$ AR was originally cloned from a human kidney library,<sup>12</sup> this receptor subtype is conspicuously absent in rat kidney where both  $\alpha_{2B}$  ( $\alpha_{2-C2}$ ) and  $\alpha_{2A}$  ( $\alpha_{2-C10}$ ) AR mRNA are found instead.<sup>25</sup> In contrast to kidney, the overwhelming majority of  $\alpha_2$ AR mRNA located in human liver appears to be the  $\alpha_{2-C2}$  subtype. Of interest,  $\alpha_{2B}$  mRNA is the only  $\alpha_2$ AR subtype present in rat liver as well—one of the few peripheral tissues where rat and human  $\alpha_2$ AR subtype mRNA distribution is identical. This finding is in agreement with the lack of  $\alpha_{2-C4}$  and  $\alpha_{2-C10}$ AR subtype mRNA found in human liver by Perala *et al.*<sup>29</sup> It is important that during the preparation of this manuscript, Eason and Liggett<sup>46</sup> published the distribution of  $\alpha_2$ AR mRNA in a number of peripheral human tissues using the method of reverse-transcription polymerase chain reaction, a technique which detects mRNA transcripts by reverse transcription into DNA template and then polymerase chain reaction amplification. Our data differ from those of this study, but quantitative comparisons are not possible in this case because the study by Eason and Liggett<sup>46</sup> contained no internal controls for efficiency of different primers or for different conditions used for each  $\alpha_2$ AR sub-

type mRNA amplification in these polymerase chain reactions.

In conclusion, this study demonstrates (1) species heterogeneity in  $\alpha_2$ AR subtype mRNA distribution for all three  $\alpha_2$ AR subtypes (rat *vs.* human); (2) the presence of all three  $\alpha_2$ AR subtype mRNAs in both human brain and peripheral tissues; and (3) the previously undescribed presence of relatively large concentrations of  $\alpha_2$ AR mRNA in adult human heart. Although this study generally defines the distribution of  $\alpha_2$ AR subtype mRNA in human tissues, it is clearly not the final answer in defining the distributions and functions of  $\alpha_2$ AR subtypes. *In situ* hybridization studies are needed to localize  $\alpha_2$ AR subtype mRNA to specific cells within human tissue samples and hence should facilitate interpretation of possible  $\alpha_2$ AR subtype selective functions. Studies of  $\alpha_2$ AR receptor protein (using highly selective ligands when they become available, and antibodies which have recently been developed) will be required to ascertain whether an  $\alpha_2$ AR subtype is physiologically important in various human tissues. These studies may also provide a possible explanation for the existence of pharmacologically similar, yet distinct  $\alpha_2$ AR subtypes, which may in turn be important for the development of  $\alpha_2$ AR subtype selective therapeutic agents for use in various human diseases. Finally, and perhaps of most interest to anesthesiologists, the elucidation of  $\alpha_2$ AR subtype distribution in human tissues provides a rational basis upon which to develop highly selective  $\alpha_2$ AR agonists for use as anesthetics and analgesics.

The authors gratefully acknowledge the helpful technical assistance of Sara Owens and the secretarial support of Betty Higgins.

## References

1. Ahlquist RP: A study of adrenotropic receptors. *Am J Physiol* 153:586–600, 1948
2. Lefkowitz RJ, Caron MG: Adrenergic receptors: Models for the study of receptors coupled to guanine nucleotide regulatory proteins. *J Biol Chem* 263:4993–4996, 1988
3. Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: Conserved structure and molecular mechanism. *Nature* 349:117–127, 1991
4. Gilman AG: G proteins: Transducers of receptor-generated signals. *Ann Rev Biochem* 56:615–649, 1987
5. Surprenant A, Horstman DA, Akbarali H, Limbird LE: A point mutation of the  $\alpha_2$ -adrenoceptor that blocks coupling to potassium but not calcium currents. *Science* 257:977–980, 1992
6. Limbird LE, The alpha-2 adrenergic receptors. Clifton, The Humana Press, 1980
7. Schmeling WT, Bloor BC: Cardiovascular effects of  $\alpha_2$ -adrenoceptors. *Anaesth Pharmacol Rev* 1:246–262, 1993



$\alpha_2$ -ADRENERGIC RECEPTOR SUBTYPE mRNA IN HUMAN TISSUES

8. Slotkin TA: Endocrine control of synaptic development in the sympathetic nervous system: The cardiac-sympathetic axis, *Developmental Neurobiology of the Autonomic Nervous System*. Edited by Gootman PM, Clifton, The Humana Press, 1980, pp 97-133
9. Weiner N, Taylor P: Neurohumoral transmission: The autonomic and somatic motor nervous systems, *The Pharmacological Basis of Therapeutics*. Edited by Gilman AG, Goodman LS, Gilman A. New York, MacMillan Publishing, 1986 pp 66-99
10. Maze M, Tranquilli W: Alpha-2 adrenoceptor agonists: Defining the role in clinical anesthesia. *ANESTHESIOLOGY* 74:581-605, 1991
11. Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW: Cloning, sequencing, and expression of the gene coding for the human platelet  $\alpha_2$ -adrenergic receptor. *Science* 238:650-656, 1987
12. Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning and expression of a human kidney cDNA for an  $\alpha_2$ -adrenergic receptor subtype. *Proc Natl Acad Sci USA* 85:6301-6305, 1988
13. Weinshank RL, Zgombick JM, Macchi M, Adham N, Lichtblau H, Branchek TA, Hartig PR: Cloning, expression, and pharmacological characterization of a human  $\alpha_2B$ -adrenergic receptor. *Mol Pharmacol* 38:681-688, 1990
14. Zeng D, Harrison JK, D'Angelo DD, Barber CM, Tucker AL, Lu Z, Lynch KR: Molecular characterization of a rat  $\alpha_2B$ -adrenergic receptor. *Proc Natl Acad Sci USA* 87:3102-3106, 1990
15. Lomasney JW, Lorenz W, Allen LF, King K, Regan JW, Yang-Feng TL, Caron MG, Lefkowitz RJ: Expansion of the  $\alpha_2$ -adrenergic receptor family: Cloning and characterization of a human  $\alpha_2$ -adrenergic receptor subtype, the gene for which is located on chromosome 2. *Proc Natl Acad Sci USA* 87:5094-5098, 1990
16. Bylund DB, Blaxall HS, Iversen IJ, Caron MG, Lefkowitz RJ, Lomasney JW: Pharmacological characteristics of alpha-2 adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. *Mol Pharmacol* 42:1-5, 1992
17. Bylund DB: Subtypes of  $\alpha_1$  and  $\alpha_2$ -adrenergic receptors. *FASEB J* 6:832-839, 1992
18. Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP: Structure and function of  $\alpha$ -adrenoceptors. *Pharmacol Rev* 43:475-505, 1991
19. Schwinn DA, Page SO, Middleton JP, Lorenz W, Liggett SB, Yamamoto K, Lapetina EG, Caron MG, Lefkowitz RJ, Cotecchia S: The  $\alpha_1C$ -adrenergic receptor: Characterization of signal transduction pathways and mammalian tissue heterogeneity. *Mol Pharmacol* 40:619-626, 1991
20. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* 18:5294-5299, 1979
21. Schwinn DA, Lomasney JW, Lorenz W, Szklut PJ, Freneau RTJ, Yang-Feng TL, Caron MG, Lefkowitz RJ, Cotecchia S: Molecular cloning and expression of the cDNA for a novel  $\alpha_1$ -adrenergic receptor subtype. *J Biol Chem* 265:8183-8189, 1990
22. Titus DE: RNA transcription in vitro, *Promega Protocols and Applications Guide*. Edited by Titus DE. Madison, Promega Corporation, 1991 pp 59-61
23. Zinn K, DiMaio D, Maniatis T: Identification of two distinct regulatory regions adjacent to the human  $\beta$ -interferon gene. *Cell* 34:865-879, 1983
24. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ: Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate. *J Urol* 150:546-551, 1993
25. Lorenz W, Lomasney JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ: Expression of three  $\alpha_2$ -adrenergic receptor subtypes in rat tissues: Implications for  $\alpha_2$  receptor classification. *Mol Pharmacol* 38:599-603, 1990
26. Voigt MM, McCune SK, Kanterman RY, Felder CC: The rat  $\alpha_2$ -c4 adrenergic receptor gene encodes a novel pharmacologic subtype. *FEBS Lett* 278:45-50, 1991
27. Lanier SM, Downing S, Duzic E, Homey CJ: Isolation of rat genomic clones encoding subtypes of the  $\alpha_2$ -adrenergic receptor: Identification of a unique receptor subtype. *J Biol Chem* 266:10470-10478, 1991
28. Handy DE, Flordellis CS, Bogdanova NN, Bresnahan MR, Gavras H: Diverse tissue expression of rat  $\alpha_2$ -adrenergic receptor genes. *Hypertension* 21:861-865, 1993
29. Perala M, Hirvonen H, Kalimo H, Ala-Uotila S, Regan JW, Akerman KEO, Scheinin M: Differential expression of two  $\alpha_2$ -adrenergic receptor subtype mRNAs in human tissues. *Mol Brain Res* 16:57-63, 1992
30. Ordway GA, Jaconetta SM, Halaris AE: Characterization of subtypes of alpha-2 adrenoceptors in the human brain. *Mol Pharmacol* 264:967-976, 1993
31. Rosin DL, Zeng D, Stornetta RL, Norton FR, Riley T, Okusa MD, Guyenet PG, Lynch KR: Immunohistochemical localization of  $\alpha_2A$ -adrenergic receptors in catecholaminergic and other brainstem neurons in the rat. *Neuroscience* 56:139-155, 1993
32. Nicholas AP, Pieribone V, Hokfelt T: Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: An in situ hybridization study. *J Comp Neurol* 328:575-594, 1993
33. Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA: Localization of mRNA for three distinct  $\alpha_1$ -adrenergic receptor subtypes in human tissues: Implications for human  $\alpha$ -adrenergic physiology. *Mol Pharmacol* 45:171-175, 1994
34. Nichols AJ, Ruffolo RR Jr: Functions mediated by  $\alpha$ -adrenoceptors,  $\alpha$ -Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology. Edited by Ruffolo RR Jr. Basel, Karger, 1991, pp 114-179
35. Lin W, Seidler FJ, McCook EC, Slotkin TA: Overexpression of  $\alpha_2$ -adrenergic receptors in fetal rat heart: Receptors in search of a function. *J Dev Physiol* 17:183-187, 1992
36. Housmans PR: Effects of dexmedetomidine on contractility, relaxation and intracellular calcium transients of isolated ventricular myocardium. *ANESTHESIOLOGY* 73:919-922, 1990
37. Flacke WE, Flacke JW, Blow KD, McIntee DF, Bloor BC: Effect of dexmedetomidine, and  $\alpha_2$ -adrenergic agonist in isolated heart. *J Cardiothorac Vasc Anesth* 6:418-423, 1992
38. Ping P, Faber JE: Characterization of alpha-adrenoceptor gene expression in arterial and venous smooth muscle. *Am J Physiol* 34:H1501-H1509, 1993
39. Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG: Molecular biology of  $\alpha$ -adrenergic receptors: Implications for receptor classification and for structure-function relationships. *Biochim Biophys Acta* 1095:127-139, 1991
40. Advenier C: Adrenergic and purinergic receptors and bronchial motoricity. *J Pharmacol* 16(suppl 1):51-70, 1985
41. Smith PH, Porte D: Neuropharmacology of the pancreatic islets. *Annu Rev Pharmacol Toxicol* 16:269-285, 1976
42. Nakadate T, Nakaki T, Kato R: Adrenergic regulation of blood glucose levels: Possible involvement of postsynaptic  $\alpha_2$ -type adren-

ergic receptors regulating insulin release. *J Pharmacol Exp Ther* 215: 226–230, 1980

43. Cherksey JW, Mendelsohn S, Zadunaisky J, Altszuler N: Demonstration of  $\alpha_2$ -adrenergic receptors in rat pancreatic islet cells using radioligand binding. *Proc Soc Exp Biol Med* 171:196–200, 1982

44. Dharmataphorn K: Alpha-2 adrenergic agonists: A newer class of antidiarrheal drug. *Gastroenterology* 91:769–770, 1986

45. Valet P, Senard JM, Devedjian JC, Planat V, Salomon R, Volsin T, Dream G, Couvineau A, Daviaud D, Denis C, Laburthe M, Paris H: Characterization and distribution of  $\alpha_2$ -adrenergic receptors in human intestinal mucosa. *J Clin Invest* 91:2049–2057, 1993

46. Eason MG, Liggett SB: Human  $\alpha_2$ -adrenergic receptor subtype distribution: Widespread and subtype selective expression of  $\alpha_{2C10}$ ,  $\alpha_{2C4}$  and  $\alpha_{2C2}$  mRNA in multiple tissues. *Mol Pharmacol* 44:70–75, 1993